Drug Trial Radar · NCT07808268
A Phase II Clinical Study to Evaluate the Efficacy and Safety of YKYY018 for Inhalation Solution
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Oct 10, 2026
Primary completion
Dec 10, 2027
Study completion Mar 10, 2028
Sponsor
- Lead sponsor
- Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase II clinical study to evaluate the efficacy and safety of YKYY018 for inhalation solution in adult participants with respiratory syncytial virus infection
Conditions
- Respiratory Syncytial Virus (RSV)
Interventions
YKYY018 for Inhalation SolutionDrug
nebulized inhalation, QD or Q2D of the corresponding dose of YKYY018 for inhalation solution
YKYY018 PlaceboDrug
nebulized inhalation, QD or Q2D of the corresponding dose of YKYY018 placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The time from initial administration to symptom relief of lower respiratory symptoms on the RiiQ (Respiratory Intensity and Impact Questionnaire) symptom scaleTime frame: within 28 days after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.